Mytos is a biotech company based in London, founded in 2016. It specializes in developing fully automated machines for growing human cells, primarily catering to large pharmaceutical and biotechnology firms involved in drug development and cell therapies. The company aims to modernize the manual process of cell culture, which is essential for early-stage drug discovery and testing.

The Mytos Platform is their core product, an automated system that combines robotics, advanced sensors, and cloud connectivity. This platform allows users to remotely manage cell culture operations, reducing human error and contamination risks. Mytos also offers the iDEM, a closed manufacturing system for pluripotent stem cells, which are vital for regenerative medicine. Their technology supports the automated production of various human cell types, enhancing the efficiency and consistency of drug development.

Mytos serves top global pharmaceutical companies and generates revenue through sales and support services for its platforms. The company is backed by prominent venture capital investors and has a skilled team with expertise in robotics, cell biology, and biotech product development.